Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries

International Health

Volumn 3, Issue 4, 2011, Pages 259-269

  Tasslimi, Azadeh ^a   Nakamura, Mari M ^b   Levine, Orin ^c   Knoll, Maria D ^c   Russell, Louise B ^d   Sinha, Anushua ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Cost effectiveness analysis; Decision analysis; Low income countries; Seven valent pneumococcal conjugate vaccine; Ten valent pneumococcal conjugate vaccine; Thirteen valent pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; ECONOMIC ASPECT; GOVERNMENT REGULATION; HEALTH CARE POLICY; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEPSIS; VACCINE PRODUCTION;

EID: 84855959564     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1016/j.inhe.2011.08.003     Document Type: Article

References (41)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
3. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1341-1348.
4. O'Brien K.L., Moulton L.H., Reid R., Weatherholtz R., Oski J., Brown L., et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003, 362:355-361.
5. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-896. Centers for Disease Control, Prevention (CDC).
6. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
7. Flannery B., Heffernan R.T., Harrison L.H., Ray S.M., Reingold A., Hadler J., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006, 144:1-9.
8. Hicks L.A., Harrison L.H., Flannery B., Hadler J., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
9. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297:1784-1792.
10. Sinha A., Levine O., Knoll M.D., Muhib F., Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389-396.
11. Drummond M.F., Sculpher M.J., Torrance B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press, New York, NY. 3rd ed.
12. WHO/UNICEF. WHO-UNICEF estimated time coverage series. WHO vaccine-preventable diseases: immunization surveillance, assessment and monitoring. Geneva: World Health Organization. [accessed 29 April 2009]. http://www.who.int/immunization_monitoring/data/data_subject/en/index.html.
13. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000, 30:100-121.
14. Constenla D, Gomez E, De La Hoz FP, O'Loughlin R, Sinha A, Valencia JE, et al. The burden of pneumococcal disease and cost-effectiveness of a pneumococcal vaccine in Latin America and the Caribbean: a review of the evidence and a preliminary economic analysis. Washington DC: Sabin Vaccine Institute; 2007. [accessed 15 August 2011]. http://www.sabin.org/files/attachment/The%2520Burden%2520of%2520Pneumococcal%2520Disease%2520and%2520Cost-Effectiveness%2520of%2520a%2520Pneumococcal%2520Vaccine%2520in%2520Latin%2520America%2520and%2520the%2520Caribbean.pdf.
15. Klugman K., Cutts F., Adegbola R.A., Black S., Madhi S.A., O'Brien K.L., et al. Meta-analysis of the efficacy of conjugate vaccines against invasive pneumococcal disease. Pneumococcal vaccines: the impact of conjugate vaccine 2008, 317-326. ASM Press, Washington, DC. G.R. Siber, K. Klugman, P.H. Makela (Eds.).
16. Hsu H.E., Shutt K., Moore M.R., Beall B., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
17. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
18. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
19. Reingold A., Hadler J., Farley M.M., Harrison L., Lynfield R., Thomas A., et al. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57:144-148.
20. Rudan I., Tomaskovic L., Boschi-Pinto C., Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 2004, 82:895-903.
21. WHO. Unit costs for patient services. Geneva: World Health Organization. [accessed 24 April 2007]. http://www.who.int/choice/costs/unit_costs/en/index.html.
22. IMF. Gross domestic product per capita, current prices. Washington DC: International Monetary Fund. [accessed 30 September 2008]. http://www.imf.org/external/ns/cs.aspx%3Fid=28.
23. Adam T., Evans D., Murray C.J. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc 2003, 1:3.
24. International Labor Organization. Minimum wage database. Geneva: International Labor Organization; 2008. [accessed 3 July 2008]. http://www.ilo.org/travaildatabase/servlet/minimumwages.
25. Management Sciences for Health International drug price indicator guide 2007, Management Sciences for Health, Boston, MA.
26. Mulligan J, Fox-Rushby JA, Adam T, Johns B, Mills A. Unit costs of health care inputs in low and middle income regions. Washington DC: World Bank, Disease Control Priorities Project (DCPP) Working Paper No. 9, revised June 2005.
27. IDA Foundation. Price Indicator. August 2006. Amsterdam: IDA Foundation. [accessed 29 August 2011]. http://www.who.int/hiv/amds/Price%20Indicator_IDA%20Foundation%20(August%202006).pdf.
28. Murray CJ, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. The Global Burden of Disease and Injury Series. Vol. 1. Boston, MA: Harvard University Press, for Harvard School of Public Health on behalf of the World Health Organization and The World Bank; 1996.
29. Fox-Rushby J.A., Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001, 16:326-331.
30. WHO. WHO statistical information system (WHOSIS). Geneva: World Health Organization; 2008. [accessed 12 October 2007]. http://www.who.int/whosis/en/.
31. WHO. Global burden of disease (GBD). Geneva: World Health Organization; 2006. [accessed 30 November 2007]. http://www.who.int/healthinfo/bodproject/en/index.html.
32. Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organization, Geneva, http://www.who.int/choice/publications/p_2003_generalised_cea.pdf [accessed 2 August 2011]. T. Tan-Torres Edejer, R. Baltussen, T. Adam, R. Hutubessy, A. Acharya, D.B. Evans (Eds.).
33. Sinha A., Ray G.T. Pharmacoeconomics of pneumococcal conjugate vaccines. Pneumococcal vaccines: the impact of conjugate vaccine 2008, ASM Press, Washington, DC. G. Siber, K. Klugman, H. Makela (Eds.).
34. WHO/UNICEF. A new approach to planning for immunization-WHO-UNICEF guidelines for developing a comprehensive multi-year plan (cMYP). Geneva: World Health Organization, United Nations Children's Fund; 2005. WHO/IVB/05.20. [accessed 10 September 2009]. http://www.who.int/immunization_financing/tools/cmyp/en/index.html.
35. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg Infect Dis 2010, 16:816-823.
36. Kaye P, Malkani R, Martin S, Slack M, Trotter C, Jit M, et al. Invasive pneumococcal disease (IPD) in England & Wales after 7-valent conjugate vaccine (PCV7); potential impact of 10 and 13-valent vaccines. [accessed 29 September 2010]. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581527892.
37. Ray G.T., Pelton S.I., Klugman K.P., Strutton D.R., Moore M.R. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009, 27:6483-6494.
38. Rozenbaum M.H., Sanders E.A., van Hoek A.J., Jansen A.G., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509.
39. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001, 285:1729-1735.
40. Simoes EAF, Cherian T, Chow J, Shahid-Salles SA, Laxminarayan R, John TJ. Acute respiratory infections in children. Disease control priorities in developing countries. 2nd ed. New York, NY: Oxford University Press; 2006. p. 483-98.
41. PneumoADIP. GSP summary report (Stage 1; Version 1) for SAGE meeting, November 6-8, 2007. Geneva: World Health Organization; 2007.